Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II - Takeaways - MDSpire

Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II

  • By

  • Xianghong Jin

  • Yixuan Li

  • Yaping Liu

  • Xianyong Jiang

  • Junling Zhuang

  • Min Shen

  • Miao Chen

  • July 13, 2026

Share

  • 1

    Porphyria cutanea tarda (PCT) can be triggered by hepatitis C virus (HCV) infection, iron overload, or environmental factors.

  • 2

    A 34-year-old man with SEC23B-mutated congenital dyserythropoietic anemia type II developed PCT associated with chronic HCV infection.

  • 3

    Initial treatment with hydroxychloroquine was ineffective, but sofosbuvir/velpatasvir achieved sustained virologic response and resolution of skin lesions.

  • 4

    The patient exhibited severe iron overload, with ferritin levels exceeding 1,200 ng/mL, contributing to oxidative stress and susceptibility to PCT.

  • 5

    This case highlights the interplay of genetic, viral, and environmental factors in the pathogenesis of PCT in patients with rare hematologic disorders.

Original Source(s)

Case Report: HCV-triggered porphyria cutanea tarda in a patient with SEC23B-mutated congenital dyserythropoietic anemia type II

  • by Xianghong Jin, Yixuan Li, Yaping Liu, Xianyong Jiang, Junling Zhuang, Min Shen, Miao Chen

  • July 13, 2026

Related Content

CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors

Evaluation of pre-dilution combined with optical/fluorescent platelet counting for correcting pseudothrombocytopenia

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min